Skip to content
Clinical Trials – home
Not yet recruiting

Phase 3 Trial Evaluating Inhaled Mosliciguat for Safety, Efficacy, and Exercise Capacity in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

People with Pulmonary Hypertension Associated with Interstitial Lung Disease have high blood pressure in the tiny vessels of the lungs caused by scarring of lung tissue, which can make breathing and exercise difficult. The study is testing an inhaled medication called mosliciguat, which is delivered as a dry powder that participants breathe in, and comparing it with a harmless inhaled placebo that looks the same but contains no active drug.

The purpose of the study is to evaluate the effect of mosliciguat compared to placebo on exercise capacity. Participants will be randomly assigned to receive either the study drug or the placebo, will use the inhaled powder twice daily, and will be followed for several months while continuing their usual care.

During the trial, participants will perform a simple walking test called the 6-Minute Walk Distance, which measures how far they can walk in six minutes, to see if the medication helps them walk farther. They will also have regular check‑ins where doctors ask about symptoms and may do routine tests to monitor safety and overall health.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Screening and Baseline Assessments

    After joining the study, you will undergo screening procedures to confirm eligibility for the trial.

    Baseline measurements will be taken, including a 6‑Minute Walk Distance test, blood samples for NT‑proBNP, and a questionnaire about symptoms of pulmonary fibrosis.

  2. Step 2

    Randomization and Allocation of Study Medication

    You will be randomly assigned to receive either the active study drug mosliciguat or a matching placebo inhalation powder.

    The medication is provided as an inhalation powder containing 4 mg of mosliciguat per dose.

  3. Step 3

    Study Period

    The trial is planned to run from December 15 2026 to August 31 2029; your participation will continue for the duration specified by the study protocol.

  4. Step 4

    Daily Inhalation of Study Medication

    You will inhale the powder according to the instructions provided by the study team.

    Each dose contains 4 mg of mosliciguat (or the placebo); the exact frequency and total length of treatment are defined by the study protocol and will be followed throughout the trial.

  5. Step 5

    Regular Follow‑up Visits

    You will attend scheduled clinic visits, typically every four weeks, where the study staff will check your health, record any side effects, and repeat the 6‑Minute Walk Distance test.

    Blood tests will be performed to measure NT‑proBNP and other safety parameters.

    You will complete the Living with Pulmonary Fibrosis symptom questionnaire at each visit.

  6. Step 6

    Safety Monitoring and Reporting

    Any adverse events you experience will be recorded and evaluated by the study team.

    You will be instructed to report new symptoms promptly, even between scheduled visits.

  7. Step 7

    End‑of‑Study Assessment

    At the final visit, all study measurements will be repeated, including the 6‑Minute Walk Distance test, blood tests, and symptom questionnaire.

    The collected data will be used to compare the effect of mosliciguat with the placebo on exercise capacity and other outcomes.

Who can join the trial?

9 criteria

  • You must be willing and able to sign a form that shows you understand the study and agree to take part (informed consent).
  • You need a diagnosis of pulmonary hypertension (high blood pressure in the lungs) that is linked to interstitial lung disease (scarring or inflammation of the lung tissue). The diagnosis will be confirmed by a special X‑ray called a high‑resolution computerized tomography (HR‑CT) scan that shows widespread damage to the lung tissue (diffuse parenchymal disease). Acceptable types of lung disease include:
    • Idiopathic interstitial pneumonia (lung scarring with unknown cause)
    • Chronic hypersensitivity pneumonitis (long‑term lung reaction to inhaled substances)
    • Interstitial lung disease related to a connective tissue disease (lung problems caused by diseases that affect joints, skin, or other tissues)
    • Your pulmonary hypertension must be confirmed by a test that measures pressure in the heart and lungs called a right heart catheterization (RHC).
    • You must be able to walk at least 100 meters (about 110 yards) during a 6‑minute walk test, which checks how far you can walk in six minutes.
    • Both men and women can join the study.
    • People of any age are allowed to participate.
    • The study can include individuals who are considered vulnerable (for example, those who may need extra protection).

Who cannot join the trial?

6 criteria

  • If you have been diagnosed with Pulmonary Hypertension (PH) Group 1, 2, 4, or 5 (these are specific types of high blood pressure in the lungs related to arteries, left‑heart problems, blood clots, or unknown causes), you cannot join the study.
  • If your lung disease got worse and needed a change in treatment or a hospital stay within the past 28 days, you cannot join the study. (An “exacerbation” means a sudden worsening of symptoms.)
  • If you need more than 10 liters per minute of oxygen while at rest, you cannot join the study.
  • If you have ever had an allergic or severe reaction to mosliciguat or other medicines called sGC stimulators or activators, you cannot join the study. (“Intolerance” means you cannot safely take the drug.)
  • If you started or are currently in the acute phase of a pulmonary rehabilitation program (a structured exercise and education program for lung disease) within the past 28 days, you cannot join the study.
  • If you received any experimental or special treatment (called “investigational or interventional therapy”) within the past 42 days, or within five times the drug’s “half‑life” (the time it takes for half of the drug to leave your body), whichever is longer, you cannot join the study.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

MOSLICIGUAT is an inhaled powder being tested in this study. Participants will breathe the medication into their lungs using a special inhaler. The drug is being evaluated to see if it can help improve the ability to exercise in people who have pulmonary hypertension linked to interstitial lung disease. Researchers are watching how safe it is and whether it can make breathing easier and increase activity tolerance.

What is already known about the treatment

Mosliciguat - Mosliciguat is delivered as a dry‑powder inhalation that patients use with a special inhaler, providing a 4 mg dose each time. It is an investigational medicine currently in Phase 3 trials and has not yet received market approval. The drug is being tested to treat pulmonary hypertension that occurs together with interstitial lung disease, a condition where the blood pressure in the lungs is too high. Mosliciguat works by stimulating soluble guanylate cyclase, an enzyme that relaxes lung blood vessels and improves blood flow, and it belongs to the class of soluble guanylate cyclase stimulators.

Investigated diseases

Pulmonary hypertension associated with interstitial lung disease - This condition combines high blood pressure in the lung arteries with scarring of the lung tissue. As the interstitial lung disease progresses, the lung tissue becomes thicker and less elastic, which narrows the small blood vessels and raises arterial pressure. The rising pressure makes it harder for blood to flow through the lungs, leading to reduced oxygen delivery during activity. Over time, the combined effects of fibrosis and vascular strain can cause a gradual worsening of breathing and exercise tolerance.
Trial detailsLast updated 18 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2026-526049-93-00Protocol codeRVT-2301-301Estimated enrolment200 patientsSponsorPulmovant Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.